Most Popular Reagents
Instruments
Antibodies
ELISA Kits
Protein Electrophoresis and Blotting
Protein and Antibody Purification
Recombinant Proteins
Molecular Biology
Stable Cell Lines
Cell Isolation and Activation
IVD Raw Materials
Therapy Applications
Resources
GenScript offers lipid nanoparticle (LNP) formulation services to support the delivery of DNA, RNA, and other molecules. Our LNP technologies enhance molecular stability, enable efficient cellular uptake, and improve bioavailability—empowering breakthroughs in therapeutic development, gene editing, and functional studies.
To further advance precision, we are excited to introduce two expanded offerings:
Variety of ionizable lipid formulation with high encapsulation efficiency
Targeted LNP Formulations available for specific cells or tissue types
ReadyEdit LNP Formulations with CRISPR RNA solutions
Try our catalog mRNA_LNP products, including SM102, LP01, and ALC0315 LNP formulations loaded with mRNA expressing eGFP, F-Luciferase or eSpCas9, delivered in just 5 days!
Our integrated IVT RNA manufacturing workflow streamlines production from gene synthesis to LNP packaging.
Codon/ Ready-to-use UTR designs
Gene
Synthesis
Cloning/ Plasmid Preparation
Lipid Nanoparticles Delivery
| Item | Test Method | Specification | RUO Standard QC | RUO Upgrade QC |
|---|---|---|---|---|
| Appearance | Visual Inspect | Clear and free of foreign particles | ||
| Final Concentration | RiboGreen assay | 0.05 – 0.4 mg/mL | ||
| Encapsulation Efficiency | RiboGreen assay | > 85% | ||
| Encapsulated RNA Integrity | Bioanalyzer | > 75% | ||
| Particle size | Dynamic light scattering |
MC3-LNP 80-110 nm SM102-LNP 65-125 nm LP01-LNP 65-125 nm ALC0315-LNP 50-100 nm |
||
| Poly Dispersity Index | Dynamic light scattering | < 0.2 | ||
| Zeta Potential | Zetasizer by dynamic light scattering | Zeta potential varies with different LNP formulations | ||
| pH | pH paper | 7.4 ± 0.5 | ||
| Endotoxin | Quantitative | <4 EU/ml | ||
| Bioburden | Direct inoculation | No Growth after 72 hrs | ||
| Lipid Composition | LC-CAD | as detected | Upon Request | |
| Antibody conjugation efficiency | Bradford assay | as detected | Upon Request |
Transfection efficiency was compared by delivering eGFP mRNA (100% N1-methyl-pseU modified, GenScript) into Jurkat and THP-1 immune cells using SM102-LNP (GenScript), Lipofectamine™ MessengerMAX™ (ThermoFisher Scientific) and TransIT® (Mirus). 100ng of mRNA were transfected into cells in 24 well plates. Starvation medium (OptiMEM) was used for lipofectamine and TransIT per the manufacturer’s instruction, and complete medium was used for LNP. The expression of eGFP was measured by flow cytometry after 48 hours.
In vivo delivery efficiency of four different LNP formulations was compared by delivering Fluc mRNA (100% N1-methyl-pseU modified, GenScript) into Balb-C mice via IM injection at a dose of 0.25mg/kg. The expression of Fluc mRNA was measured by whole-body bioluminescence imaging.
Fluc mRNA delivered by MC3-LNP showed the highest expression level after 8 and 48 hours by imaging at both Dorsal and Ventral pose of mice. To evaluate the biodistribution profile of different formulations, the heart, liver, lung, spleen, kidney, and brain of the mice were collected and imaged after 48 hours, MC3 -LNP formulation showed the strongest liver accumulation compared to others after 48 hours.
In vivo delivery efficiency of two different LNP formulations was compared by delivering Fluc mRNA (100% N1-methyl-pseU modified, GenScript) into Balb-C mice via IV injection at a dose of 0.3mg/kg. The expression of Fluc mRNA was measured by whole-body bioluminescence imaging.
In imaging analysis, Fluc-mRNA delivered by SM102-LNP showed higher expression efficiency than MC3 after 8 and 48 hours. To evaluate the biodistribution profile of different formulations, heart, liver, lung, spleen, kidney, and brain of the mice were collected and imaged after 48 hours, SM102 -LNP showed stronger liver accumulation compared to MC3-LNP after 48 hours. MC3-LNP showed stronger spleen accumulation after 48 hrs. Neither formulation caused significant body weight loss during the experiment period for 3 days.
LNP Case Study Report
Case studies demonstrating encapsulation and delivery efficiency of GenScript’s new LNP formulations in cell models, and mouse models via both IM and IV.
Free Download
Questions On Storage And Usage Guidelines_mRNA, saRNA and LNP
Free DownloadLipid nanoparticles (LNPs) are natural or synthetic molecules that can self-assemble into a spherical structure. LNPs are typically composed of lipid layer, which forms a shell around an inner compartment that can be used to deliver drugs or other therapeutic agents. LNPs have become increasingly popular as a drug delivery system due to their ability to protect therapeutic agents from degradation and improve their bioavailability. They can also be designed to target specific cells or tissues, allowing for more precise delivery of drugs. LNPs have been used in various applications, including the delivery of RNA-based therapeutics such as mRNA vaccines. The lipid layer of LNPs can fuse with the cell membrane, allowing the encapsulated RNA to enter the cell and exert its therapeutic effect. LNPs have also been investigated as a potential delivery system for other types of drugs, including small molecules and proteins.
Our LNP service encapsulates 20nt - 10knt RNA.
All of these LNP formulation (MC3 / SM102/ ALC0315 or LP01) are not active targeting formulations, so they tend to accumulate in the liver instead of targeting to specific tissues. However, if you need organ-specific LNP, we can offer customized formulation per the customer's request. Please reach out to our technical support team for details.
We recommend SM102 and ALC0315 LNPs for mRNA, these two has shown great efficiency in delivery mRNA in vivo. You can acquire off-the-shelf LNP loaded with mRNA coding for marker gene to perform initial studies for their project needs.
MC3-LNP has been successfully used in siRNA delivery previously.
Yes, We can formulate multiple guide RNA and Cas9 mRNA into one LNP formulation. GenScript also provides sgRNA synthesis service up to 160nt long and customized Cas9 virants mRNA production.
Yes, we do. Please reach out to our technical support team for details.
Yes, we do. Please reach out to our technical support team for details.
We use microfluidic device and chip to prepare LNP.
The final encapsulation efficiency is >90%. However, we expect ~50% payload loss during the encapsulation process. For example, 2mg payload input could expect 1mg encapsulated, with a variance of ±10% in final amount encapsulated.
We suggest to order 200ug of mRNA for encapsulation.
Typical concentration we provide is 0.1-0.4 mg/ml. The highest concentration we can provide is 2mg/mL.
For the LNP final buffer solution, we use Tris buffer which will enable longer-term stability compared with PBS, according to the research results from Moderna. We also offer the option of using PBS with sucrose or Tris with sucrose as the final buffer for LNP. Sucrose is used as a cryoprotectant. Default buffer is PBS with sucrose.
We suggest to thaw LNP and keep at 4°C after thaw for up to 1 month. Dilute with PBS or tris based on your final buffer.
If you plan to store LNP for longer than 3 months, it is recommended to add a cryoprotectant. GenScript will ship LNP in default buffer PBS with sucrose on dry ice. We recommend to store LNP at -80°C upon receipt until use. Avoid freeze-thaw cycles. Suggest to thaw on the day of use, otherwise keep your thawed LNP at 4°C for up to 1 month.
The LNP should be stable for at least 3 months if stored properly at -80°C upon receival and avoiding repeated freezing and thawing cycles. The amount of freeze/thaw cycles depends on the mRNA length. For 1-2kb, we suggest not to freeze/thaw more than 2 times. For 2-5kb, we suggest no more than once freeze/thaw. If you need to thaw the LNP, it is suggested to thaw them on ice and keep the thawed formulation at 4°C.
Same protocol can be used for adherent and immune cell lines as well.
